FDA approves Wyeth's hemophilia therapy

Wyeth has won FDA approval Xyntha, a treatment for patients with hemophilia A, a rare blood-clotting disorder in which sufferers lack a key protein (Factor VIII) that prevents excessive bleeding. Xyntha is a genetically engineered version of the missing blood protein that's essential for clotting. "This recombinant Factor VIII is produced without additives from human or animal material, which further minimizes any risk of infection from the product," said Jesse Goodman, director of FDA's CBER. The product is entirely synthetic; previous treatments for the disease used monoclonal antibodies derived from mouse cell lines. About 15,000 people in the U.S. suffer from the disease.

- check out the release
- and here's the FDA's statement on the approval

Suggested Articles

Although BridgeBio has grown from one program to 21 within five years, it will present four top prospects to investors during an R&D day on Tuesday.

Dewpoint Therapeutics aims to advance research in one of the more mysterious cell organelles: biomolecular condensates.

The FDA slapped a partial clinical hold on the phase 2/3 study of Inovio’s COVID-19 vaccine because it has “additional questions” about the trial.